Protara Therapeutics, Inc.
TARA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.30 | -0.10 | 0.09 | 0.68 |
| FCF Yield | -6.77% | -9.58% | -8.51% | -6.67% |
| EV / EBITDA | -15.00 | -6.10 | -6.14 | 1.32 |
| Quality | ||||
| ROIC | -10.86% | -11.18% | -8.68% | -8.34% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.94 | 0.82 | 1.23 | 0.73 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | -1.50% | 16.84% | -58.54% | -10.26% |
| Safety | ||||
| Net Debt / EBITDA | 0.76 | 1.67 | 6.21 | 11.13 |
| Interest Coverage | -9.83 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -4,606.36 | 0.00 | 0.00 | 0.00 |